Post-authorisation Safety Study (PASS): Retrospective Medical Chart Review of Patients with PAH Newly Treated With Either Uptravi® (selexipag) or any Other PAH-specific Therapy (EXTRACT)

First published 06/10/2022

Last updated 15/08/2024

EU PAS number:

EUPAS49227

Study

Finalised

Documents

Study protocol

Initial protocol

15Aug2024-REDACTED_Protocol-FD-67896049PAH0002-588005_1363699.pdf

English (1009.78 KB - PDF) View document

Study results

15Aug2024-REDACTED_Interim CSR #7-Body-67896049PAH0002_AC-065A401-1119952_1363698.pdf

English (2.52 MB - PDF) View document

Study report

Other information

Secondary tabs